Investing.comDoubao · 实盘不做把握 6/10不做原因:风险收益比不佳
北京时间·🕒 发布 20:36:29·⟳ 抓取 20:36:57 +28s·⚡ 决策 10-19 20:39:36 +2m39s·8.0 天前
FDA批准Alpha Tau Medical的REGAIN胶质母细胞瘤试验扩容：入组上限由10人增至20人，并新增IDH突变4级肿瘤患者
本次仅是first-in-human安全性/可行性试验入组人数翻倍（10→20人）的IDE补充批准，不提供新疗效证据，距任何商业化收入极远；实质性疗效催化（100%局部控制、67% CR）已于5月11日、6月11日两次释放，本次为边际增量。消息在盘前以仅约1.4万股的极薄量能推高约7.9%，开盘追入跳空缺口、而真正的新数据要等11月13日SNO，风险收益比不足。
📄 原文Investing.com↗ 原文
FDA expands Alpha Tau glioblastoma trial to 20 patients
Oil prices dip as Trump waives Russia sanctions JERUSALEM - Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced Monday that…
不做 Alpha Tau Medical Ltd.（DRTS.US）
边际性临床去风险事件（安全性试验10→20人扩容、无新疗效数据、无收入），真正的疗效surprise已于5月/6月释放；盘前以约1.4万股极薄量能跳空+7.9%，开盘追高风险收益比不足，下一个实质催化为11月13日SNO数据，等待数据或回踩承接确认后再评估
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
FDA允许REGAIN试验由10人扩至20人并扩大入组人群，是对Alpha DaRT胶质瘤项目的温和去风险，但无新增疗效数据且不产生收入；盘前薄量跳空约8%已部分定价，真正数据催化在11月13日，不追高，回避。
🔎 新鲜度:最早出现 2026-10-19 · 扩散 low · price-in 风险 medium ↗
消息传播链
- Investing.com（AI生成、编辑审核）转述公司新闻稿：FDA批准IDE补充，REGAIN扩至20人、纳入IDH突变4级、新增PFS终点，SNO 11月13日报告市场反应:美股盘前DRTS报13.26美元，较前收12.29美元+7.9%，盘前成交约1.43万股
关键理由
- 扩容与新增IDH突变4级人群适度扩大了该早期项目的临床验证范围和可见度，方向偏正面
- 11月13日SNO将披露新数据，构成未来约3.5周的已知催化日历
主要风险
- REGAIN仍为单臂、开放标签的安全性/可行性研究（n将达20），早期仅3例的高响应率存在小样本失效风险，且无商业化批准
- 盘前+7.9%仅由约1.4万股成交驱动，常规时段可能高开低走，真实承接未经证实
反向证据
- 做多前查反向 · 来源 web · 日期 2026-08-10 · 影响 weakens
公司8月10日发布二季报，作为无收入的临床期公司持续亏损（PE为负），近20日股价-19.36%、10月16日单日-6.61%，存在融资摊薄与情绪走弱背景，削弱追多胜率
检索:DRTS Alpha Tau stock decline October 2026 cash burn dilution offering 原文 ↗ - 做多前查反向 · 来源 filing · 日期 2026-10-19 · 影响 weakens
新闻稿明确Alpha DaRT在试验外未获商业化批准、研究仍为早期安全性/可行性单臂试验，新增中期分析本身也隐含安全性审视；未见取消试验或安全事件等否决性信息
检索:REGAIN glioblastoma trial safety risk interim analysis Alpha DaRT 原文 ↗
先例如何影响了这次决策
对本次决策的影响:缺乏高相似对齐先例加上边际催化性质，支持以小仓投机也不参与、等待11月13日数据的回避结论
方向:公司层面同项目的前两次节点（2026-05-11早期疗效中期、2026-06-11完成入组许可）方向均为正面，但事件强度均高于本次
涨幅量级:无可与本次（IDE扩容10→20人、无新数据）对齐相位、且有精确首发时刻锚点的同市场先例；5月/6月官网新闻稿仅能确认日期，无法满足首发时刻锚定要求，故不做量化幅度校准
形态:早期临床里程碑后股价波动剧烈（近20日累计-19%，5月数据曾推动上行），表明数据驱动型行情对纯程序性进展的持续性存疑
工具执行结果 · 成功 5 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 11 ms
{"result": "search_processed_events:agent query=`alpha tau medical fda ide supplement regain glioblastoma trial 20 patients | drts alpha dart recurrent glioblastoma fda expansion november sno presentation`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agent query 表达式没有召回候选，不能据此证明消 - fetch_decision_experience 成功 stock_tools_inprocess · 1 ms
{ - stock_quote 成功 stock_tools HTTP · 198 ms
{ - web_search 成功 doubao_search · 2,087 ms
豆包搜索结果（原始查询:Alpha Tau Medical REGAIN glioblastoma FDA IDE supplement 20 patients press release；API SearchType:web） - web_search 成功 doubao_search · 1,913 ms
豆包搜索结果（原始查询:DRTS Alpha Tau Medical stock clinical trial expansion reaction May 2026 interim results glioblastoma；API SearchType:web）
原文全文
展开原文 · 2,186 字
Oil prices dip as Trump waives Russia sanctions
JERUSALEM - Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced Monday that the U.S. Food and Drug Administration has approved an Investigational Device Exemption supplement expanding its REGAIN trial for recurrent glioblastoma treatment.
The approval allows the trial to enroll up to 20 patients, double the previously authorized 10 patients, at three U.S. academic cancer centers. The updated protocol also opens the study to patients with IDH-mutant grade 4 tumors, adds progression-free survival as a secondary endpoint, and introduces regular quality-of-life assessments, according to a press release statement.
The protocol includes an additional interim analysis six months after the fifth patient’s treatment, which occurred in July 2026.
An abstract authored by REGAIN principal investigator Dr. Joshua Palmer of The Ohio State University has been accepted for presentation at the Society for Neuro-Oncology Annual Meeting, scheduled for November 12-15, 2026, in Philadelphia. The presentation, titled "First-In-Human Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma: Safety Interim Analysis," will take place on November 13 from 7:30 to 9:30 p.m. ET.
The presentation will include new trial data, building on interim results from the first three treated patients that Alpha Tau announced on May 11, 2026.
REGAIN is a prospective, interventional, open-label, single-arm, multicenter study designed to evaluate the feasibility and safety of Alpha DaRT for treating recurrent glioblastoma. The study enrolls patients whose recurrent glioblastoma or IDH-mutant grade 4 tumor is not amenable to surgical resection and who have undergone prior central nervous system radiation.
Alpha Tau develops Alpha DaRT, an alpha-radiation cancer therapy that delivers radium-224 impregnated sources intratumorally. The Alpha DaRT treatment has not been approved for commercialization or use for treating recurrent glioblastoma outside approved clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
JERUSALEM - Alpha Tau Medical Ltd. (NASDAQ:DRTS) announced Monday that the U.S. Food and Drug Administration has approved an Investigational Device Exemption supplement expanding its REGAIN trial for recurrent glioblastoma treatment.
The approval allows the trial to enroll up to 20 patients, double the previously authorized 10 patients, at three U.S. academic cancer centers. The updated protocol also opens the study to patients with IDH-mutant grade 4 tumors, adds progression-free survival as a secondary endpoint, and introduces regular quality-of-life assessments, according to a press release statement.
The protocol includes an additional interim analysis six months after the fifth patient’s treatment, which occurred in July 2026.
An abstract authored by REGAIN principal investigator Dr. Joshua Palmer of The Ohio State University has been accepted for presentation at the Society for Neuro-Oncology Annual Meeting, scheduled for November 12-15, 2026, in Philadelphia. The presentation, titled "First-In-Human Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma: Safety Interim Analysis," will take place on November 13 from 7:30 to 9:30 p.m. ET.
The presentation will include new trial data, building on interim results from the first three treated patients that Alpha Tau announced on May 11, 2026.
REGAIN is a prospective, interventional, open-label, single-arm, multicenter study designed to evaluate the feasibility and safety of Alpha DaRT for treating recurrent glioblastoma. The study enrolls patients whose recurrent glioblastoma or IDH-mutant grade 4 tumor is not amenable to surgical resection and who have undergone prior central nervous system radiation.
Alpha Tau develops Alpha DaRT, an alpha-radiation cancer therapy that delivers radium-224 impregnated sources intratumorally. The Alpha DaRT treatment has not been approved for commercialization or use for treating recurrent glioblastoma outside approved clinical trials.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
0fb3e9744b· 2026-10-19 20:39 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前